News

Press Releases

N30 Pharma Announces Financing, Expansion of Board

October 28 2008, 6:00AM MSTBOULDER, Co -- N30 Pharma (N30), a biopharmaceutical company focused on the discovery, development, and commercialization of drugs that regulate nitric oxide bioavailability, announced today that it has completed a financing and expanded its Board of Directors.N30 will use proceeds from this financing to advance its clinical program in Cystic Fibrosis and expand its discovery and preclinical research in the area of small molecule drugs tha...  Read More

N30 Pharma Announces Successful Initiation of Human Studies With N30-201

Jan 28 2008, 1:00 AM EST

BOULDER, Co -- N30 Pharma (N30), a biopharmaceutical company focused on the discovery, development, and commercialization of respiratory drugs that target endogenous s-nitrosothiols, announced today that it has successfully completed Phase 1 study of N30-201 in healthy volunteers. N30 intends to develop N30-201 for the treatment of reactive and obstructive airway diseases, including Cystic Fibrosis and asthma.

“We are pleased to have beg...  Read More

N30 Pharma Announces License Agreement With NitroMed, Inc.

Monday October 29, 12:27 PM EST

BOULDER, Co. -- N30 Pharma (N30), a biopharmaceutical company focused on the discovery, development, and commercialization of respiratory drugs that target endogenous s-nitrosothiols, today announced a licensing agreement with NitroMed Inc. (Nasdaq: NTMD - News) covering the respiratory use of a s-nitrosothiol drug candidate...  Read More